Navigation Links
New Colon Cancer Test Might Spot Trouble Earlier
Date:1/24/2008

That and other findings reported at symposium on gastrointestinal cancers

THURSDAY, Jan. 24 (HealthDay News) -- Researchers say they have zeroed in on a biomarker that could detect colorectal cancer in its earliest stages in a simpler, less invasive and more accurate way than existing blood tests.

The marker, called colon cancer-specific antigen-2 (CCSA-2), could also differentiate between early- and late-stage disease, the researchers added.

The study was one of several concerning colon cancer being presented at the annual Gastrointestinal Cancers Symposium being held Jan. 25 to 27 in Orlando, Fla.

A second study found that patients who are uninsured or who have coverage with Medicaid tend to be diagnosed with colorectal cancer at a later stage than individuals with private insurance or Medicare. This is the first nationwide survey to confirm similar findings from smaller polls.

And a third study is a step on the road to so-called personalized medicine. "This study assesses the benefit of treatment with a monoclonal antibody for colorectal cancer patients based on their tumor's molecular signature," Dr. Nicholas Petrelli, an official with the symposium, said during a Wednesday teleconference on the findings.

According to the American Cancer Society, colorectal cancer is the third most common cancer among American men and women. Some 150,000 new cases are diagnosed each year in the United States.

Regular screening can catch the disease while it is still curable. Colon cancer can also be prevented if polyps and adenomas are found and removed before they become malignant.

There are already blood tests for colorectal cancer, but they result in false-positives in 60 percent to 90 percent of cases, depending on the test, said the authors of the first study.

The researchers, from Johns Hopkins University and the University of Pittsburgh, looked at 135 blood samples from individuals who had undergone colonoscopies. They were compared with samples from individuals with other types of cancer or with benign diseases.

Only about 20 percent of results were false positives, while only 9 percent of cancers went undetected.

There was also a correlation between the level of CCSA-2 in the blood and the size of the growth. The highest levels of CCSA-2 indicated the presence of actual cancer. The study was funded by Onconome, which has licensed the patent for the test from the University of Pittsburgh researchers.

The second study, conducted by the American Cancer Society, found that patients without health insurance were almost two times more likely and Medicaid patients 40 percent more likely to be diagnosed with stage II colon cancer rather than stage I disease, compared to those with Medicare or private insurance.

And again, uninsured patients were twice as likely while Medicaid patients were 50 percent more likely to be diagnosed with stage III or IV colon cancer than patients in the other insurance categories. The results held steady no matter where the cancer was found.

Minorities, females, older patients, those who lived in areas with low-income and low-education levels and those who were treated at non-research teaching hospitals were more likely to be diagnosed with advanced cancer.

"Improved access to screening and medical care in these populations may be able to reduce these disparities," said study author Dr. Michael Halpern, strategic director of health services research at the American Cancer Society.

And the third study confirmed that only patients who have a normal form of the KRAS gene in their tumors will benefit from the monoclonal antibody Vectibix (panitumumab). Mutations are found in 30 percent to 50 percent of colorectal cancer patients. The study was funded by Amgen, which makes the drug.

More information

Visit People Living With Cancer for more on colorectal cancer.



SOURCES: Jan. 23, 2008, teleconference with Nicholas Petrelli, M.D., official, Gastrointestinal Cancers Symposium; Michael T. Halpern, M.D., Ph.D., strategic director, health services research, American Cancer Society


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. New Colonial Life Brand Clarifies Companys Strengths
2. Colonoscopy fears overcome when patients support patients
3. Colon cancer risk in US traced to common ancester
4. Photo: KFC Colonel Original and Look-a-Like Share Eye Treatment Success Story
5. Colon cancer screenings may not pay off and could pose harm to some
6. Genes May Explain Role of Race in Colon Cancer Risk
7. Rural patients colon and lung cancers diagnosed earlier, Dartmouth research says
8. Narrow band imaging colonoscopy identifies flat dysplastic lesions in ulcerative colitis patients
9. CT colonography detects wide-range of extracolonic abnormalities in elderly patients
10. Drug Helps Fight Late-Stage Colon Cancer in Some Patients
11. Panacea Pharmaceuticals Announces the Availability of CC Detect(SM), a Serum-Based Diagnostic Test for Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Colon Cancer Test Might Spot Trouble Earlier
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: